A Phase I study evaluating the safety and immunogenicity of MVA85A, a candidate TB vaccine, in HIV-infected adults

A Phase I study evaluating the safety and immunogenicity of MVA85A, a candidate TB vaccine, in HIV-infected adults

Bibliographic Details
Main Authors:	Minassian, Angela M, Rowland, Rosalind, Beveridge, Natalie E R, Poulton, Ian D, Satti, Iman, Harris, Stephanie, Poyntz, Hazel, Hamill, Matthew, Griffiths, Kristin, Sander, Clare R, Ambrozak, David R, Price, David A, Hill, Brenna J, Casazza, Joseph P, Douek, Daniel C, Koup, Richard A, Roederer, Mario, Winston, Alan, Ross, Jonathan, Sherrard, Jackie, Rooney, Guy, Williams, Nicola, Lawrie, Alison M, Fletcher, Helen A, Pathan, Ansar A, McShane, Helen
Format:	Online
Language:	English
Published:	BMJ Group 2011
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3221299/

Similar Items

Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults
by: Pathan, Ansar A., et al.
Published: (2012)

Th1/Th17 Cell Induction and Corresponding Reduction in ATP Consumption following Vaccination with the Novel Mycobacterium tuberculosis Vaccine MVA85A
by: Griffiths, Kristin L., et al.
Published: (2011)

Safety and immunogenicity of an FP9-vectored candidate tuberculosis vaccine (FP85A), alone and with candidate vaccine MVA85A in BCG-vaccinated healthy adults: A phase I clinical trial
by: Rowland, Rosalind, et al.
Published: (2013)

Evaluation of a Human BCG Challenge Model to Assess Antimycobacterial Immunity Induced by BCG and a Candidate Tuberculosis Vaccine, MVA85A, Alone and in Combination
by: Harris, Stephanie A., et al.
Published: (2014)

Correction: Safety and Immunogenicity of Boosting BCG Vaccinated Subjects with BCG: Comparison with Boosting with a New TB Vaccine, MVA85A
by: Whelan, Kathryn T., et al.
Published: (2011)

Boosting BCG with Recombinant Modified Vaccinia Ankara Expressing Antigen 85A: Different Boosting Intervals and Implications for Efficacy Trials
by: Pathan, Ansar A., et al.
Published: (2007)

Roles for Treg Expansion and HMGB1 Signaling through the TLR1-2-6 Axis in Determining the Magnitude of the Antigen-Specific Immune Response to MVA85A
by: Matsumiya, Magali, et al.
Published: (2013)

Effects of MVA85A vaccine on tuberculosis challenge in animals: systematic review
by: McShane, Helen, et al.
Published: (2016)

Optimising Immunogenicity with Viral Vectors: Mixing MVA and HAdV-5 Expressing the Mycobacterial Antigen Ag85A in a Single Injection
by: Betts, Gareth, et al.
Published: (2012)

Correction: Boosting BCG with Recombinant Modified Vaccinia Ankara Expressing Antigen 85A: Different Boosting Intervals and Implications for Efficacy Trials
by: Pathan, Ansar A., et al.
Published: (2011)

Serum indoleamine 2,3-dioxygenase activity is associated with reduced immunogenicity following vaccination with MVA85A
by: Tanner, Rachel, et al.
Published: (2014)

Inflammatory and myeloid-associated gene expression before and one day after infant vaccination with MVA85A correlates with induction of a T cell response
by: Matsumiya, Magali, et al.
Published: (2014)

A first-in-human phase 1 trial to evaluate the safety and immunogenicity of the candidate tuberculosis vaccine MVA85A-IMX313, administered to BCG-vaccinated adults
by: Minhinnick, Alice, et al.
Published: (2016)

Correction: Safety and Immunogenicity of the Candidate Tuberculosis Vaccine MVA85A in West Africa
by: Brookes, Roger H., et al.
Published: (2011)

The Candidate TB Vaccine, MVA85A, Induces Highly Durable Th1 Responses
by: Tameris, Michele, et al.
Published: (2014)

A Human Challenge Model for Mycobacterium tuberculosis Using Mycobacterium bovis Bacille Calmette-Guérin
by: Minassian, Angela M., et al.
Published: (2012)

Process of Assay Selection and Optimization for the Study of Case and Control Samples from a Phase IIb Efficacy Trial of a Candidate Tuberculosis Vaccine, MVA85A
by: Harris, Stephanie A., et al.
Published: (2014)

Effects of MVA85A vaccine on tuberculosis challenge in animals: systematic review
by: Kashangura, Rufaro, et al.
Published: (2015)

Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: a phase 1, double-blind, randomised controlled trial
by: Satti, Iman, et al.
Published: (2014)

Preclinical Development of an In Vivo BCG Challenge Model for Testing Candidate TB Vaccine Efficacy
by: Minassian, Angela M., et al.
Published: (2011)

Two Doses of Candidate TB Vaccine MVA85A in Antiretroviral Therapy (ART) Naïve Subjects Gives Comparable Immunogenicity to One Dose in ART+ Subjects
by: Dieye, Tandakha N., et al.
Published: (2013)

Potent CD8+ T-Cell Immunogenicity in Humans of a Novel Heterosubtypic Influenza A Vaccine, MVA−NP+M1
by: Berthoud, Tamara K., et al.
Published: (2011)

A Phase I, Open-Label Trial, Evaluating the Safety and Immunogenicity of Candidate Tuberculosis Vaccines AERAS-402 and MVA85A, Administered by Prime-Boost Regime in BCG-Vaccinated Healthy Adults
by: Sheehan, Sharon, et al.
Published: (2015)

Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV-1: a randomised, placebo-controlled, phase 2 trial
by: Ndiaye, Birahim Pierre, et al.
Published: (2015)

Correction: Two Doses of Candidate TB Vaccine MVA85A in Antiretroviral Therapy (ART) Naïve Subjects Gives Comparable Immunogenicity to One Dose in ART+ Subjects
by: Dieye, Tandakha N., et al.
Published: (2013)

Evaluation of Xpert® MTB/RIF Assay in Induced Sputum and Gastric Lavage Samples from Young Children with Suspected Tuberculosis from the MVA85A TB Vaccine Trial
by: Bunyasi, Erick Wekesa, et al.
Published: (2015)

Percutaneous Vaccination as an Effective Method of Delivery of MVA and MVA-Vectored Vaccines
by: Meseda, Clement A., et al.
Published: (2016)

Acquisition of direct antiviral effector functions by CMV-specific CD4+ T lymphocytes with cellular maturation
by: Casazza, Joseph P., et al.
Published: (2006)

DNA/MVA Vaccines for HIV/AIDS
by: Iyer, Smita S., et al.
Published: (2014)

Correction: MVA.85A Boosting of BCG and an Attenuated, phoP Deficient M. tuberculosis Vaccine Both Show Protective Efficacy Against Tuberculosis in Rhesus Macaques
by: Verreck, Frank A. W., et al.
Published: (2011)

Improvement of BCG protective efficacy with a novel chimpanzee adenovirus and a modified vaccinia Ankara virus both expressing Ag85A
by: Stylianou, E., et al.
Published: (2015)

Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8+ T cell responses
by: Precopio, Melissa L., et al.
Published: (2007)

Cholera Toxin Enhances Vaccine-Induced Protection against Mycobacterium Tuberculosis Challenge in Mice
by: Griffiths, Kristin L., et al.
Published: (2013)

Ciliopathy in PCS (MVA) syndrome
by: Miyamoto, Tatsuo, et al.
Published: (2015)

Non-tuberculous mycobacteria have diverse effects on BCG efficacy against Mycobacterium tuberculosis☆
by: Poyntz, Hazel C., et al.
Published: (2014)

The Future of Smallpox Vaccination: is MVA the key?
by: Slifka, Mark K
Published: (2005)

The relationship between EVA, MVA and leverage
by: J.H., de Wet, et al.
Published: (2004)

Gene Expression and Cytokine Profile Correlate With Mycobacterial Growth in a Human BCG Challenge Model
by: Matsumiya, Magali, et al.
Published: (2015)

Loss of Circulating CD4 T Cells with B Cell Helper Function during Chronic HIV Infection
by: Boswell, Kristin L., et al.
Published: (2014)

Factoring 51 and 85 with 8 qubits
by: Geller, Michael R., et al.
Published: (2013)